title: A quantitative homogeneous assay for fragile X mental retardation 1 protein.
abstract: BACKGROUND
  Hypermethylation of the fragile X mental retardation 1 gene FMR1 results in decreased expression of FMR1 protein FMRP, which is the underlying cause of Fragile X syndrome - an incurable neurological disorder characterized by mental retardation, anxiety, epileptic episodes and autism. Disease-modifying therapies for Fragile X syndrome are thus aimed at treatments that increase the FMRP expression levels in the brain. We describe the development and characterization of two assays for simple and quantitative detection of FMRP protein.
  
  
  METHODS
  Antibodies coupled to fluorophores that can be employed for time-resolved Förster's resonance energy transfer were used for the development of homogeneous, one-step immunodetection. Purified recombinant human FMRP and patient cells were used as control samples for assay development.
  
  
  RESULTS
  The assays require small sample amounts, display high stability and reproducibility and can be used to quantify endogenous FMRP in human fibroblasts and peripheral blood mononuclear cells. Application of the assays to FXS patient cells showed that the methods can be used both for the characterization of clinical FXS patient samples as well as primary readouts in drug-discovery screens aimed at increasing endogenous FMRP levels in human cells.
  
  
  CONCLUSIONS
  This study provides novel quantitative detection methods for FMRP in FXS patient cells. Importantly, due to the simplicity of the assay protocol, the method is suited to be used in screening applications to identify compounds or genetic interventions that result in increased FMRP levels in human cells.
authors.affiliation: Neuroscience Discovery, Novartis Pharma AG, Novartis Institutes for Biomedical Research, Postfach, Basel, CH-4002, Switzerland. Andreasweiss@Email.com.
authors.forename: Gabi
authors.initials: G
authors.lastname: Schutzius
authors.forename: Dorothee
authors.initials: D
authors.lastname: Bleckmann
authors.forename: Sandra
authors.initials: S
authors.lastname: Kapps-Fouthier
authors.forename: Francesco
authors.initials: F
authors.lastname: di Giorgio
authors.forename: Bernd
authors.initials: B
authors.lastname: Gerhartz
authors.forename: Andreas
authors.initials: A
authors.lastname: Weiss
references.citation: Am J Hum Genet. 1999 Jul;65(1):98-103
references.pmid: 10364521
references.citation: Neuron. 2007 Dec 20;56(6):955-62
references.pmid: 18093519
references.citation: Nat Genet. 1999 May;22(1):98-101
references.pmid: 10319871
references.citation: Cell. 1991 Aug 23;66(4):817-22
references.pmid: 1878973
references.citation: Genet Med. 2001 Sep-Oct;3(5):359-71
references.pmid: 11545690
references.citation: J Mol Diagn. 2009 Jul;11(4):281-9
references.pmid: 19460937
references.citation: Trends Neurosci. 2004 Jul;27(7):370-7
references.pmid: 15219735
references.citation: J Biol Chem. 2012 Sep 28;287(40):33691-705
references.pmid: 22843695
references.citation: Eur J Hum Genet. 2011 Apr;19(4):489-91
references.pmid: 21267007
references.citation: Clin Biochem Rev. 2008 Aug;29 Suppl 1:S49-52
references.pmid: 18852857
references.citation: J Biomol Screen. 1999;4(2):67-73
references.pmid: 10838414
references.citation: Am J Med Genet A. 2008 May 15;146A(10):1358-67
references.pmid: 18412117
references.citation: PLoS Genet. 2008 Mar 07;4(3):e1000017
references.pmid: 18369442
references.citation: Cell. 2003 Feb 7;112(3):317-27
references.pmid: 12581522
references.citation: Pediatrics. 2009 Jan;123(1):378-90
references.pmid: 19117905
references.citation: Nat Genet. 1993 Aug;4(4):335-40
references.pmid: 8401578
references.citation: Sci Transl Med. 2011 Jan 5;3(64):64ra1
references.pmid: 21209411